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Abstract (150 to 250 words) 
The advances in medicine have achieved great benefits by improving or even 
eliminating various debilitating diseases or malignancies, expanding life expec-
tancy. However, it has also originated the development of a compromised popula-
tion susceptible to opportunistic diseases. A global major concern is the emer-
gence and spread of life-threatening invasive infections in immunocompromised 
patients, in which the opportunistic fungal infections have greatly increased in the 
last decades. The high mortality rates associated with these infections, which re-
main as high as 40%, are due to the limited therapeutic options and the emergence 
of drug resistant fungi, but also due to the lack of efficient early diagnosis. Conse-
quently, these facts led to the opinion that new approaches are needed to improve 
the outcome of these patients, such as immunopreventive strategies that could 
even be combined with standard antifungal treatment. In view of the proven effec-
tiveness of various antibacterial and antiviral vaccines in preventing the respective 
diseases, several works have been developed to induce protective immunity 
against fungal infections as well. The better understanding of how the immune 
system works against fungal pathogens has made possible to explore immuno-
modulatory strategies that can protect both immunocompetent and immunocom-
promised hosts and generate memory. Recently, two fungal vaccines against Can-
dida have advanced through clinical trials. However, there are still many 
challenges in the development of an efficient vaccine against invasive fungal in-
fections. We will provide an update on the progress made in immunization against 
fungal infections, reviewing host-fungi interactions, antigens and adjuvants ex-
ploited in vaccine strategies, and discuss concerns that need to be overcome to fur-
ther advance in the area of fungal vaccines. 
 
 
1. Candida and its relation with the host 
 
In healthy individuals, Candida colonization, as part of the normal human 
microbiota, remains generally benign without any symptoms of disease [1, 2]. 
Tolerance of the immune system towards commensal species and maintenance of 
a homeostatic balance at the mucosal surfaces reflects a series of strategies such as 
avoidance of immune recognition, active suppression of the host response, and 
regulation of the immune response by the host, as well as the normal mucosal mi-
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crobiota, confining microbes to this surface [2, 3]. However, when tissue homeo-
stasis is disrupted, Candida might penetrate the forbidden compartments of host 
tissues and cells, causing pathologies, ranging from recalcitrant skin/mucosal in-
fections to life-threatening systemic infections. The deep-seated or the disseminat-
ed infections have increased in frequency particularly in patients with medical 
conditions and treatments that affect natural barriers of the body or negatively im-
pact the competence of the immune system. Such treatments include the use of 
broad-spectrum antibiotics, prosthetic devices and grafts, burn injuries or surgery, 
and medical conditions refer to patients with leukemia, neutropenia or under 
chemo and immunosuppressive therapies and patients with HIV infection [4]. The 
current methods to protect susceptible individuals from these opportunistic infec-
tions include prophylactic use of antifungal agents or protective environments 
such as rooms with controlled air flow. Although it is accepted that early, pre-
sumptive treatment of patients with invasive candidiasis is a major determinant of 
survival, such strategies have not been validated by prospective studies [5].  
In Intensive Care Units (ICU) Candida spp colonization may occur in up to 
80% of critically ill patients, but curiously, the proportion of invasive candidiasis 
is less than 10 % [6, 7]. Therefore, the immune system is important for the 
maintenance of integrity at the mucosal surface and, even in an immunocompro-
mised state, Candida species remain in the benign commensal state rather than in 
the invasive pathogenic one. Indeed, some studies suggest that C. albicans may 
evolve to avoid confrontation with the host, favoring commensalism [8, 9]. How 
the immune system distinguishes these dual behavior, commensal vs pathogenic is 
a fundamental question in the development of immune preventive strategies 
against commensal species, and particularly Candida species.  
The development of new immunotherapies, including vaccines, is driven 
by the progress made in the understanding of the molecular pathogenic mecha-
nisms of the infectious agent. Understanding how mucosal homeostasis is estab-
lished, maintained or disrupted during fungal exposure and/or colonization should 
help to guide the development of new immunotherapies. Knowledge about the 
immune response against Candida infections has greatly increased in this last dec-
ade, with new data and reviews emerging frequently [10-16]. Thus, a brief review 
to the immune responses to Candida developed at the mucosa surface will be pre-
sented. 
 
1.1 Within the mucosal layers: interaction of Candida albicans with the epi-
thelium  
The mucosal epithelium is a critical barrier and the frontline of sensing mi-
crobes. Due to its commensal nature the initial interaction of Candida with the 
human immune system is frequently via epithelial cells of the mucosa [17, 18]. 
There are multiple ways to contain C. albicans in the mucosa, such as the micro-
bial flora or the active role of epithelial cells that produce antimicrobial peptides 
[15]. In addiction, epithelial cells secrete mucins that establish a protective film, 
forming a dense lattice close to the epithelial surface in which secreted antimicro-
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bial molecules are embedded [19]. Curiously, it has been described that in the gas-
tric mucosa this mucin film is organized into two layers, an inner layer (50 µm 
thick) that is densely packed, firmly attached to the epithelium and devoid of mi-
crobes, in contrast to the outer layer (100 µm thick) that is movable, has an ex-
panded volume due to proteolytic cleavages of the mucins and is colonized by mi-
crobes [20]. Recently, it was described that mucin induces an oval-shaped 
morphology in C. albicans in which genes related to adhesion, filamentation, and 
biofilm formation are downregulated [21] and that mucin has an inherent direct 
candidacidal activity [22]. Mucosal epithelial cells express innate immune recep-
tors or pattern-recognition receptors (PRRs) that recognize microbe-associated 
molecular patterns (MAMPs), allowing the immune system to detect attachment 
of microbes and act accordingly. However, the PRR that mediates recognition of 
fungi in epithelial cells are still largely unknown or undefined. The major known 
PRRs involved in the recognition of Candida cells were identified in the phago-
cytic cells and includ the Toll-like receptors (TLRs), C-type lectin receptors 
(CLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs) [15]. 
Among the 13 TLRs discovered, expression of TLR1 through TLR9 has been 
identified in human intestinal epithelial cells (IECs) [23], but its expression varies 
in different organisms and different mucosal surfaces (oral, vaginal or gastric) 
[17]. In addition, TLR2 and TLR4 that are important for host anti-Candida de-
fences [14, 24] have demonstrated hyporesponsiveness to their ligands in human 
IECs [23]. Furthermore, by using a model of oral reconstituted human epithelium 
(RHE) TLR2, and particularly TLR4, seem to be highly responsive to Candida 
MAMPs [25]. Expression of CLR in epithelial cells seems to be restricted to 
dectins. Human IECs express functional Dectin-1 that recognizes fungal β-glucans 
[26], and bronchial epithelial cells also express Dectin-1, which plays an im-
portant role in the control of Aspergillus fumigatus infections [27]. As a result of 
the long co-evolution of fungi, and particularly C. albicans with mucosal surfaces 
having particular environments, the cross-talk between fungi in the different mu-
cosal surfaces has evolved in multiple ways under the double constraints of sens-
ing microbes and adjusting the immune response to the perceived degree of threat 
while maintaining homeostasis at the mucosa.  
Fungal cells differ from animal cells primarily due to the cell wall that sur-
rounds their plasma membrane. The Candida cell wall structure has two distinct 
layers, an outer layer mainly composed of mannan and mannoproteins (O- and N-
linked glycoproteins), and an inner layer that contains the skeletal polysaccharides 
chitin, β-1,3-glucan and β-1,6-glucan, which confer strength and shape to the 
yeast cells [28]. These cell wall molecules, which are absent from the human 
body, are the major source of MAMPs for recognition by host PRRs. However, 
much of these molecules are expressed in both the commensal state and in the 
pathogenic state. Recently it was suggested that the pathogenic state may be rec-
ognized by “patterns of pathogenesis” or POP rather than only by microbial mo-
lecular structures [29]. In this hypothesis, MAMPs are delivered along with addi-
tional information that can be used by the host to distinguish pathogenic from non-
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pathogenic state and thereby guide the ensuing innate immune response. During 
such pathogenic behaviors, MAMPs access forbidden compartments of host tis-
sues and cells, being recognized by PRRs as genuine pathogen-associated molecu-
lar patterns (PAMPs) and elicit an appropriate immune response. This POP hy-
pothesis does not define a pathogen, but a pathogenic behavior that can be adopted 
by any microbe. This allows a particular microbe to be considered a commensal or 
a pathogen, depending on time and context. Its pathogenicity is determined by its 
interaction with the host, and can change with host, location in the host, and the 
immune state of the host [3]. The cross-talk between Candida albicans and the 
immune system can also be integrated into this hypothesis. It is well established 
that Candida show different behaviors, the pathogenic (invasive) and the non-
pathogenic (commensal) [1, 15, 30], but favoring commensalism [8, 9].  
One sign of POP that has been defined is the microbial over-growth in their 
host [3]. Epithelial cells are able to actively monitor the density of resident micro-
biota by sampling microbial molecules through PRRs [23]. It is of particular sig-
nificance that mucosal epithelial cells are able to discriminate between the com-
mensal and the pathogenic behavior of C. albicans cells, and there are several 
ways to control yeast over-growth [11, 31, 32]. The majority of the epithelial 
TLRs and Dectin-1 signal through MyD88 adaptor, leading to a transcriptional re-
sponse primarily dependent on the transcription factor NF-κB [15, 23]. In com-
mensalism the presence of C. albicans yeast or hyphae triggers the NF-κB signal-
ing pathway and an early response of the mitogen-activated protein kinase 
(MAPK) activation through ERK1/2 and JNK signaling. At the mucosal surfaces 
this response leads to the secretion of IL-22, by innate and adaptive immune cells, 
that stimulates the proliferation of epithelial cells and, together with IL-17, the 
production of antimicrobial peptides, controlling fungal growth and tissue homeo-
stasis [12, 31]. However, when C. albicans outgrows and a high fungal hyphal 
burden is present the threshold level of the MAPK activation is reached and a se-
cond pathway, the MAPK/MKP-1/c-Fos is activated [31]. Activation of this se-
cond response results in the production of proinflammatory cytokines, such as in-
terleukin 1α/β (IL-1α/β), IL-6, GM-CSF, TNF-α and chemokines, RANTES, IL-
8, and CCL20 that induce the recruitment, differentiation, and activation of vari-
ous immune cells, including phagocytes [11, 31]. This immune activation results 
in reduction of fungal burdens back down below the threshold level of activation 
and thus to the commensal state. One additional way to modulate C. albicans pop-
ulation density is through quorum sensing, in which molecules produced during 
continuous C. albicans growth, act as inhibitors of the yeast-to-hypha transition 
[1, 33], and both morphological forms are known to be required for virulence [34]. 
Curiously, the recently described non-lytic expulsion of internalized hyphal Can-
dida cells by macrophage after phagocytosis benefits not only the immune cells, 
avoiding their own lysis, but also the fungus as it escapes from intracellular death 
[35]. This suggests that re-establishment of homeostasis does not implicate the 
complete elimination of the fungus, but rather reduction of its burden to the com-
mensal state. Thus, at the mucosal surface there is a constant cross-talk between C. 
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albicans and host mucosal immune system in order to keep the fungal burden be-
low a certain threshold and maintain homeostasis [31].  
Another POP behavior is cytosolic invasion, as many pathogens deliver ac-
tive proteins, or virulence factors to access forbidden compartments of host tissues 
[3]. When perturbations at the mucosa surface occur, such as the composition of 
the competitive commensal bacteria that may result from antibiotic use, or when 
the immune system becomes severely weakened by factors such as HIV infection, 
chemotherapy, or chirurgic interventions, the proper restriction of C. albicans may 
fail as well as the capacity to control its over-growth, predisposing individuals to 
Candida invasion. If containment at the mucosa is breached, the yeast proliferates 
and penetrates forbidden compartments of the host tissues. Candida albicans has 
the ability to invade host epithelial cells by two routes: via active penetration and 
via induced endocytosis [36, 37]. The active penetration is exclusively a fungal at-
tribute and includes the physical pressure applied by the advancing hyphal growth 
in combination with the secretion of extracellular hydrolases like proteases, phos-
pholipases and lipases [15, 38]. The induced endocytosis is the passive uptake of 
C. albicans cells through yeast surface proteins Als3p and Hgc1p by the E-
cadherin receptor in host epithelial cells [38].  
As stated above, the epithelial cells actively monitor resident microbes by 
sampling microbial molecules and channels that transport microbial cell wall 
components into epithelial cells [23]. To aid in the consequent epithelial response, 
several PRRs are intracellular, cytoplasmic, and are involved in pathogen recogni-
tion, antigen processing and presentation, production of antimicrobial β-defensins, 
and activation of the inflammasomes. The inflammasome is a multiprotein com-
plex that triggers the post-translational activation of caspase-1 that in turn cleaves 
and activates the secretion of a variety of substrates, including pro-interleukin-1β 
and pro-interleukin-18, leading to an inflammatory response [15]. These PRRs re-
ceptors are not exposed to pathogens unless they get into the cells, when invading 
mucosa, like TLR3 and TLR9 that recognize fungi nucleic acids, or NOD2 that 
recognize fungal chitin [39, 40]. It has also been reported that this activation may 
induce the maintenance of a minimal level of “physiological inflammation” by ac-
tivating NOD proteins in the cytoplasm of gut epithelial and immune cells. Curi-
ously, recognition of fungal chitin by NOD2, together with TLR9 and the man-
nose receptor, are essential for the selective secretion of the anti-inflammatory 
cytokine IL-10 by phagocytic cells [41]. This exerts a collaborative control in 
which TLR signaling is required for the transcription of pro-IL-1β and pro-IL-18, 
and the post-translational inflammasome response is then required for subsequent 
cleavage and secretion of the active cytokine. This dual control may be an im-
portant regulatory mechanism to limit inappropriate or unnecessary production of 
cytokines that trigger potent responses that may be potentially damaging to the 
host, particularly concerning commensal organisms. Thus, the immune system can 
initiate responses based not only on whether PAMPs are present, but also on 
where those PAMPs are presented, allowing the epithelium to adjust the response 
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to the perceived degree of threat and return to the homeostatic state once the path-
ogen has been controlled. 
 
1.2 Beyond the mucosal layers: overview of the immune response against 
Candida infections 
At the mucosal epithelium, Candida may assume a fully pathogenic be-
havior, invading deeper tissues, gaining assess to the blood stream and causing in-
vasive infections [11, 12]. One of the causes of this drastic rupture of homeostasis 
is a too weak immune system. The life-threatening opportunistic Candida infec-
tions occur particularly in immunocompromised patients in which the immune 
forces that normally contain C. albicans and establish equilibrium are at risk of 
being overwhelmed. 
The host immune system responds with the innate immune attack as the 
immediately acting primary line of defense against fungi penetration. Recognition 
of fungal-associated PAMPs will lead to the initiation of a host defense that is 
mandatory to limit fungal burden in order to clear the invading fungus from non-
authorized sites [11, 15]. The cell populations that orchestrate this initial response 
include the phagocytic cells: neutrophils, macrophages and dendritic cells (DCs) 
[10, 13, 15]. 
Macrophages are considered the first line of defense since they are dis-
tributed in various tissues as resident cells. Macrophages exhibit a considerable 
phenotypic diversity and functional plasticity that confer them the ability to effi-
ciently respond to stimuli. The fungal cell wall is a dynamic structure that is con-
tinuously changing throughout the fungus cell cycle and during morphological 
transition. During tissue invasion macrophages readily ingest the round yeast form 
of C. albicans as well as relatively short filaments. The development of hyphae 
triggers the recognition of cell wall β-glucans via the Dectin-1/inflammasome 
pathway. Engagement of Dectin-1 induces not only direct macrophage activation 
and internalization of the fungus but it also has a synergistic effect on TLR2 and 
TLR4 responses, via NF-κB activation, leading to IL-1β production and T helper 
cell 17 (Th17 cell) activation [32, 42, 43]. However, upon hyphal growth C. albi-
cans is able to shield β-glucans with surface mannans as a mechanism to evade 
cellular phagocytosis [18]. Thus, other PAMPs, such as mannans and mannopro-
teins, are also recognized by several CLRs, including Mannose Receptor, Dectin-
2, dendritic cell DC-SIGN, and MINCLE [14, 44]. Dectin-2, mainly expressed on 
dendritic cells, macrophages and neutrophils recognizes Candida α-mannan and, 
together with Dectin-3 has been reported to form heterodimers, mediating Can-
dida uptake by the phagocyte and leading to pro-inflammatory responses during 
C. albicans infection, also via NF-κB activation [10, 45].  
In consequence of the inflammatory response neutrophils migrate to the 
site of infection and after recognition of Candida cells, they can directly kill the 
yeast cells, inhibit their growth and the yeast-to-hyphal transition, limiting in this 
way the progression of fungus [46]. The importance of these phagocytes is high-
lighted by the observation that the depletion of mononuclear phagocytes results in 
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accelerated fungal proliferation in tissues and increased mortality [47], and that 
neutropenic patients or patients with impaired neutrophil function are more sus-
ceptible to systemic fungal infections [46]. Phagocytic clearance of C. albicans 
involves the accumulation of phagocytes at the site where the yeast cells are locat-
ed, and engulfment and killing of fungal cells after the recognition of cell-surface 
fungal PAMPs [48]. These innate immune cells damage or kill C. albicans cells 
by using a combination of oxidative and non-oxidative mechanisms that includes 
the production of antimicrobial peptides and degradative enzymes, and the genera-
tion of antimicrobial reactive oxygen species (ROS)/nitric oxide synthase (iN-
OS)[49, 50]. Human neutrophils and macrophages express constitutively chitotrio-
sidase (CHIT-1), an enzyme that promotes digestion of fungal cell wall chitin, and 
whose expression increases significantly during the end/late-phase of infection 
[41]. Curiously, low concentrations of small chitin particles have been shown to 
induce IL-10 secretion, via NOD2 and TLR9 signalling [41]. This mechanism has 
been proposed to contribute to the resolution of the infection when the pathogen 
has been defeated by the immune system, promoting the attenuation of inflamma-
tory-mediated diseases and consequent immune homeostasis. 
The innate immune system not only specifically recognizes diverse mi-
croorganisms, but also initiates and modulates the subsequent adaptive responses 
that are delivered by T cells and B cells through their interactions with antigen-
presenting cells. Phagocytic DCs play an essential role in the activation of adap-
tive immune responses, being one of the most efficient antigen presenting cells 
(APCs). DCs are important for processing and presenting fungal antigens but, due 
to the dual nature of C. albicans, their reaction to this fungus must be flexible in 
order to shape T-cell responses accordingly. Th1 responses involving proinflam-
matory cytokines, such as IFN-γ and TNF-α, were considered protective against 
fungal infections whereas Th2 responses, with the secretion of IL-4 and IL-10, 
were believed to enhance host susceptibility [16]. However, with the identification 
of Th17 response, involving proinflammatory cytokines IL-17 and IL-22, this is 
now considered a major pathway for protection against fungal infections [12]. 
These cytokines induce neutrophil recruitment and activation, as well as the acti-
vation of epithelial cells and release of antifungal β‑defensins, being important at 
the mucosal surface. The importance of Th17 in anti-Candida response was con-
firmed by the identification of functionally specific Th17 clones that respond to C. 
albicans by releasing IL-17 and IFN-γ, but not IL-10 [51]. Indeed, patients with 
defects in Th17 immunity have been directly linked to increased susceptibility to 
chronic mucocutaneous candidiasis (CMC) [52]. After recognition of Candida, the 
plasticity of DCs is reflected into distinct signaling pathways that are translated in-
to different in vivo adaptive immune responses [53]. Inflammatory DCs initiate 
antifungal Th17/Th2 cell responses to yeast through signaling pathways that in-
volve adaptor MyD88, whereas tolerogenic DCs activate Th1/Treg (T regulatory) 
cell responses to hypha through TRIF adaptor [16, 53]. 
The balance between proinflammatory and anti-inflammatory signals is 
essential for successful host/pathogen interaction in fungal infections in which 
8  
Treg cells play a critical role [53]. Treg cell, essentially via production of IL-10, 
are able to inhibit components of innate and adaptive immunity in order to regu-
late the host’s immune defense to an adequate level; a protective response without 
total elimination of the fungus and preventing an exacerbated level of tissue dam-
age [16, 53]. However, overly potent Treg suppression can inhibit protective im-
munity, favoring the pathogen. Nevertheless, since Treg cells control the quality 
and magnitude of innate and adaptive effector responses the outcomes may range 
from protective tolerance to overt immunosuppression, determining the balance 
between commensalism and pathogenicity. At the mucosa, a local anti-
inflammatory/tolerogenic response through secretion of IL-10 and TGF-β, would 
allow for the fungus persistence, whereas beyond the mucosa, an appropriate in-
flammatory immune response, is necessary to eliminate the fungus and return to a 
homeostasis state.  
The role of Th17 responses in systemic fungal infection is somehow con-
troversial since, on one hand it is described that IL-17RA-/- and IL-17A-/- mice 
have elevated susceptibility to disseminated candidiasis [54, 55] and IL-17A me-
diates vaccine induced protection in mice [56]. On the other hand, humans with 
mutations in the IL-17 pathway typically do not develop disseminated disease [55] 
and candidemic patients showed significantly higher levels of IL-17A than pa-
tients without invasive candidiasis [57]. The idea that elevated Th17 and Treg re-
sponses are harmful in disseminated candidiasis seemingly contrasts with the ap-
parent protective role of IL-17 in mice. In disseminated candidiasis it has been 
reported that C. albicans drives expansion of a complex Treg cell population that 
by depletion of IL-2 promotes the development of Th17 responses that are associ-
ated with immune pathology and with C. albicans survival and dissemination [58] 
[55].  
Th17 and Treg subsets are reciprocally regulated during naïve T cell dif-
ferentiation. However, it is clear that IL-17/Th17 and Treg cells have a complex 
relationship and that the outcome of the response to Candida depends on the site 
of infection in which the corresponding microenvironment is able to shape these 
responses. At the intestinal mucosa, high levels of transforming growth factor beta 
(TGF-β) and retinoic acid have been found that together with short chain fatty ac-
ids (SCFAs) from commensal microbes fermentation support tolerogenic Tregs, 
favoring C. albicans commensalism. In contrast, internal organs are shielded from 
the external environment, and thus inflammation induced during disseminated C. 
albicans infection is more likely to go unchecked, resulting in collateral tissue 
damage by Th17 responses [55, 58]. Together, these data underline the importance 
of the balance between proinflammatory and anti-inflammatory responses for both 
susceptibility to acquire invasive candidiasis and ability to clear the infection, 
once it has disseminated. 
 
In addition to the cellular responses adaptive B-cell, by inducing antibody 
mediated memory responses, may neutralize adherence and spread on and/or 
through epithelial and endothelial tissues. The role of antibodies in the defense 
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against candidiasis has been controversial due to the believe that immunocom-
promised patients, the main targets of opportunistic fungal infections, were unable 
to develop adequate adaptive B-cell response. In addition, due to the fact that 
Candida are commensal organisms, natural anti-Candida antibodies may be pre-
sent in the serum of normal individuals but no correlation with these antibodies 
and protection to a subsequent infection has been observed. 
There is now substantial evidence for the important role of antibody-
mediated immunity in clearance of infectious agents, including host resistance to 
systemic candidiasis. Regarding the class of immunoglobulins, it has been pro-
posed that IgM titers against intracellular proteins that are not localized to the cell 
wall would be higher in patients with systemic candidiasis than in controls, which 
suggests that these antigens might be less visible to the humoral immune system 
during commensal growth [59]. However, Regarding the subclass, a recent study 
evaluated how the IgG subclass of an anti-Candida antibody influences its biolog-
ical functions, using the mouse model [60]. Four IgG subclass variants of the hu-
man antimannan antibody, Mg1, M1g2, M1g3, and M1g4, equivalent to IgG1, 
IgG2, IgG3, and IgG4, were constructed and evaluated. They found that the four 
IgG subclasses differ in protection against hematogenously disseminated candidia-
sis in mice, with IgG1, IgG3, and IgG4 being more effective than IgG2. This dif-
ference has been attributed to the lower capacity of IgG2 to mediate FcγR-
dependent phagocytic clearance. All variants promoted deposition of both murine 
and human complement C3 onto the yeast cell surface however IgG4 was less po-
tent in activating the complement system. The fact that IgG4 was less potent in ac-
tivating the complement system but induced similar levels of protection than 
IgG1, IgG3, and was even more protective than IgG2, suggests that the role of the 
complement system in mediating protection may not be that determinant. Indeed, 
in a murine model of cryptococcosis it was found that complement-nonactivating 
human IgG2- or IgG4-mouse chimeric antibodies are protective, while comple-
ment-activating human IgG1- or IgG3-mouse chimeric antibodies are nonprotec-
tive [61]. 
The study of the immunoglobulins present in the serum of human sub-
jects without signs of infection in comparison with patients with proven systemic 
candidiasis has also contributed to the identification of proteins that could be spe-
cifically recognized in each situation. The antibodies identified specifically in sub-
jects without infection were considered as natural anti-Candida antibodies and are 
believed to arise from the commensal relation with the host. Some of the natural 
anti-Candida antibodies identified Candida, Eno1p, Pgk1p, Adh1p, and Pdc11p, 
are abundant metabolic enzymes present in the yeast cell wall [62]. However, only 
antibodies against Pgk1p and Adh1p seem to differentiate patients with systemic 
candidiasis from non-infected subjects. Antibodies against glyceraldehyde-3-
phosphate dehydrogenase (Gap1p), phosphoglycerate kinase (Pgk1p), phospho-
glycerate mutase (Gpm1p), enolase (Eno1p), pyruvate kinase (Cdc19p), aconitase 
(Aco1p), methionine synthase (Met6p), hyphal wall protein (Hwp1), mannan, 
among others have been identified specifically in patients with systemic candidia-
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sis. However, conditions that make the molecular targets available to the immune 
system to induce antibodies differ according to many variables, including the 
morphology changes of the pathogens, the competence of the immune system at 
the entry port, the composition of the commensals and their similarity of epitopes, 
and the history of antimicrobial treatments that have different modes of action, 
among others. All these mechanisms contribute to expose antigenic molecules to 
the immune system and some treatments will increase/alter exposure of certain an-
tigenic molecules. This may be one of the reasons why it has been so difficult to 
identify antibodies/antigenic molecules that would be useful for immunoglobulin-
based prophylactics and therapeutics. Nevertheless, Mycograb (NeuTec Pharma) a 
human recombinant antibody anti-Hsp90p was found to be therapeutically effec-
tive in combination with amphotericin B in patients with systemic candidiasis in a 
randomized, blinded, multicenter trial [63].  
These studies evidence that the role of antibody-mediated resistance to 
fungal infections is important and may be exploited as new therapeutic approaches 
however, the isotypes that could be more effective in a response that involves an-
tibodies must be carefully chosen to mimicking the host’s natural protective anti-
body and balance between its disease-causing effects, as exacerbated complement 
activation, and its effects on clearance of microbes. 
Intense investigation of immunological mechanisms involved in fungal infec-
tions means that we are closer to understanding the processes involved in the iden-
tification and clearance of pathogens from the human body and in establishing 
immune memory to respond to future exposure. The ideal vaccine would initiate 
an innate immune response capable of directing the adaptive immune response 
toward efficient inactivation and removal of the specific pathogen from non-
allowed sites, followed by the development of adequate immune memory. In the 
next section, an up-date of the studies toward the development of vaccination 
strategies will be presented. 
 
 
2. Induction of immunity in experimental models  
 
2.1 Concerns about the development of preventive strategies 
The increasing incidence and severity of invasive fungal infections cou-
pled with diagnostic difficulties and high cost of treatments prompted the investi-
gation on vaccination [64]. However, for years the development of fungal vac-
cines has lagged behind that of vaccines against bacteria and viruses because of 
the idea that most patients who develop life-threatening fungal infections have 
profound defects in their immune systems and are unable to respond to vaccina-
tion. Indeed invasive Candida infections often takes place in hospital settings, 
however it is has been estimated that only 10–20% of patients who develop blood-
stream infection from Candida are seriously immunocompromised. The large ma-
jority develop the infection after patient’s normal bacterial flora is disrupted by 
antibiotics, or when their skin or gut mucosa are breached by burns, central ve-
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nous catheters or surgery [4, 5, 65]. Furthermore, several studies confirmed the 
immunogenicity and efficacy of vaccines in seriously immunocompromised pa-
tients, such as those with active leukemia, HIV infections, or cancer patients [66-
68]. Thus, immunocompromised patients are able to respond to vaccination and 
vaccination has been recommended to patients with HIV and cancer despite their 
weakened immune systems [69-71]. It has been assumed that acutely ill hospital-
ized patients whose primary host defense defect is anatomical will also respond to 
vaccination [65]. In the case of Candida systemic infections the various medical 
procedures that are identified as risk factors, such as exposure to broad spectrum 
antibiotics, central venous catheters or major surgery are perfectly recognized, 
opening a window of opportunity to vaccinate at-risk patients even before the on-
set of infection [72-74]. In addition, prevention of infectious disease in the elderly 
has become a priority in the 21st century as the proportion of older individuals in-
creases globally. Fungal infection, due to Candida, Aspergillus and Cryptococcus 
are known to be more frequent in the extreme of the ages, children and elder pa-
tients. 
Consistent with Benjamin Franklin’s dictum ‘an ounce of prevention is 
worth a pound of cure’, preventive therapies against invasive candidiasis may re-
duce the severity of these infections. A vaccine that could prevent or improve the 
outcome of fungal infections would not only benefit the at-risk patients but also be 
of major benefit for national healthcare systems by reducing hospital costs. 
 
 
2.2 Evidences from systemic candidiasis in the human host 
Several studies were undertaken to identify Candida albicans immunogenic 
proteins specifically recognized by antibodies produced during the natural course 
of systemic Candida infection and that could be exploited for vaccine develop-
ment or even as useful biomarkers for diagnosis. One of the earliest studies evalu-
ated, by immunoblotting, 201 sequential serum samples from 45 patients with sys-
temic candidiasis in which 13 were involved in an outbreak at London Hospital 
[75]. This study showed a high heterogeneity in antibody response but was able to 
identify an antibody against a 47 kD antigen present in all patients that recovered 
from the systemic infection. Latter, the 47 kD antigen was identified as a break-
down product of heat-shock protein (Hsp) 90 from C. albicans. The presence of 
antibodies against a 47 kD antigen in serum of other patients with systemic can-
didemia with a favorable outcome has also been identified by other independent 
studies. Serum from these patients passively transferred to mice infected with a le-
thal dose of C. albicans was able to induce protection, and a monoclonal antibody 
raised against a synthesized conserved epitope (LKVIRK) of Hsp90p reduced 
mice mortality when given 24h before an i.v.  challenge [76]. This antibody seems 
to protect through neutralization of the protein-binding activity of Candida circu-
lating Hsp90p or by inhibition of Candida growth [77]. However, an epitope map-
ping analysis indicated that antibodies reacting to epitopes of this protein showed 
100% direct homology with comparable sites on human Hsp90p, raising the con-
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cern of development of autoimmune reactions. These studies showed that patients 
who recover from systemic candidiasis may produce autoantibodies against self-
epitopes. 
More recently another study used a highly sensitive proteomic approach to 
identify potential candidate markers for diagnosis and follow-up of systemic can-
didiasis [62]. This study identified immunoreactive protein species that were pre-
sent in patients with proven candidemia and also in patients with no apparent 
Candida infection. In patients with invasive candidiasis the authors were able to 
unambiguously identify 42 different C. albicans protein targets of the human im-
mune response. The abundance of housekeeping enzymes, most of them (65%) 
metabolic enzymes was discussed, as among other possibilities, being part of an 
universal signal for infection. Since these are ubiquitous and highly conserved en-
zymes their epitopes can be shared by several infectious agents and allow the de-
velopment of a natural resistance to infection. The identifications of these proteins 
by the immune system may be considered as part of the “patterns of pathogenesis” 
response. Among the metabolic enzymes, that are also present on the C. albicans 
cell surface, antibodies against Glyceraldehyde-3-phosphate dehydrogenase 
(Gap1p), Phosphoglycerate kinase (Pgk1p), Phosphoglycerate mutase (Gpm1p), 
Enolase (Eno1p), Pyruvate kinase (Cdc19p), Aconitase (Aco1p), Methionine syn-
thase (Met6p) had already been identified in human serum previously. Several 
other proteins, including Hxk2p (hexokinase) and Pgi1p and 6-
phosphofructokinase were identified as antigens of the immune system for the first 
time in this study. Curiously, antibodies against C. albicans proteins Eno1p, 
Fba1p, Tkl1p, Ino1p, Met6p, Sah1p, Ilv5p, Ade17p, Qcr2p increased in response 
to antifungal treatment, indicating that their exposure to the immune system in-
creased with the antifungal treatment. From this survey 14% of the identified tar-
gets were chaperons and heat shock proteins, including Ssa1p and Ssb1p identified 
in previous studies as antigens, and Ssc1p and Sse1p newly identified as antigens 
in this study. Curiously, the 47-kDa fragments of Hsp90p identified previously 
[75] was not identified in this analysis, only the 82-kDa fragment of the same pro-
tein. The C. albicans elongation factor 1 (Eft1p) and Eft2p, known to be located in 
the cell wall and proposed as potential antigens for vaccine development were also 
found in this study.  
The protein targets identified in the serum of subjects with no infection were 
considered as targets of natural anti-Candida antibodies. These natural antibodies 
identified Candida Eno1p, Pgk1p, Adh1p, and Pdc11p, which corresponded to 
abundant glycolytic and fermentative enzymes. The natural antibodies were con-
sidered to be elicited during commensal colonization by C. albicans or against 
other homologue protein from different commensals or infectious agents that 
cross-react with C. albicans proteins. This study also identified targets that could 
be correlated with recovery from systemic candidiasis in humans, like high serum 
levels of anti-Eno1p antibodies, the appearance or maintenance of anti-Hsp90p, 
anti-Tpi1p, or the disappearance of serum anti-Met6p or anti-Pgk1p antibody lev-
els. 
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Another study measured IgG and IgM titers in the serum of human systemic 
Candida infections against 15 specific recombinant C. albicans antigens [59]. It is 
documented that patients with systemic candidiasis already exhibit significantly 
high IgG titers against a wide range of antigens (ENO1, HWP1, mannan, and 
CGTA) before or at the time that the diagnosis is confirmed by a positive blood 
culture. This study suggests that invasive candidemia may be preceded by low-
level systemic exposure to Candida spp., possibly due to “leakage” from mucosal 
sites of colonization. 
 
 
2.3 Exploited protection strategies against candidiasis 
 
2.3.1 Whole cells vaccines 
The need for therapeutic or preventive use of a vaccine in candidiasis, 
particularly in certain groups of at risk patients is reflected in the huge number of 
experimental investigations designed to attempt induction of protection. The early 
studies trace back to the decade of 50’s. 
One of the early documented studies repeatedly immunized rabbits intra-
venously (i.v.) with heat-killed C. albicans prior to infection and then assessed 
survival, histopathology of infected organs and passive immunization. The authors 
concluded that this immunization did not result in protection and that the anti-
Candida antibodies induced by vaccination did not protect the animals [78]. Lat-
ter, by using the same model but immunizing with heat-killed and heat-weakened 
Candida, protection was only observed in rabbits immunized with viable Candida, 
and histological analysis indicated that cellular immunity was important [79]. 
These observations point to the active action of the pathogen in the immunization 
process. In the murine model low virulent Candida strains, modified in the fila-
mentation capacity and stress response, where shown to provide protection against 
a subsequent intravenous systemic Candida infection [80-82]. The efficacy of the-
se strategies reached 100% for all strains at least in one evaluated condition. Other 
study, using the mouse model, also observed the importance of fungal pathogenic-
ity on priming of mice with Candida [83]. Naive BALB/c mice were intraperito-
neally (i.p) primed with a low inoculum of Candida yeast cells that were heat-
killed, deliberately attenuated or in its pathogenic native form. One month later 
mice were infected with the pathogenic strains and only the mice primed with the 
pathogenic native form were able to clear the infection. Live-attenuated pathogens 
or in its pathogenic native form have been shown to be especially immunostimula-
tory when used as vaccines. This may be explained by the hypothesis that the im-
mune system also responds to POP and suggest why killed strains failed to elicit 
protection [29]. However, due to the complexity of antigens and the inexistence of 
generalizable procedure for how best to attenuate pathogens for their use as vac-
cines, attenuated strains challenge safety requirements. However, changing to a 
subcutaneous (s.c.) immunization with a Candida sonicate, Mourad and Friend-
man (1968) were able to protect 50% of mice, obtaining the best result in compar-
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ison with viable or killed C. albicans cells. In addition, they observed that trans-
ferring passively anti-Candida serum to naïve mice conferred them protection 
against a subsequent systemic candidiasis [84]. After these results, subcellular an-
tigens have been further exploited as candidates for augmenting host defense and 
vaccine development against candidiasis.  
 
2.3.2 Ribosomal vaccines 
Ribosomal subcellular vaccines derived from both procaryotic and eucar-
yotic pathogens were widely exploited as protectors and afforded high levels of 
protection at small dose levels, being the duration of the immunity they provided 
greater than the ones obtained with previous antigens used. Thus, ribosomal frac-
tions were also used to try to induce protection against candidemia. Studies docu-
mented that it was possible to induce protection by immunization with C. albicans 
ribosomes, not only against heterologous C. albicans strains, with 30-78% of sur-
vival, but also cross protection against C. tropicalis isolates, with 57 to 64% of 
survival rate from a systemically administered lethal infection [85]. Ribosomal 
vaccine was also exploited in experimentally induced cell-mediated immunocom-
promised mice, resulting in a survival rate that reached 76% [86]. This vaccine 
was also exploited in tumor-bearing mice and although the survival rate did not 
change, it was able to expand the median survival time [87]. These results showed 
that vaccination of immunocompromised and tumor-bearing hosts with Candida 
ribosome could provide enhanced resistance to disseminated candidiasis. These 
works encouraged the continuing studies in immunization against candidiasis and 
revealed the immunogenicity of subcellular components and the role of antibodies 
in the protection. A variety of cell constituents, routes of administration and proto-
cols have been tested and despite the degree of variability in the results observed, 
induction of protection was considered possible. However due to the complexity 
of the antigen, that would probably include mRNA, rRNA and ribosomal proteins, 
newly synthesized polypeptides along with other cell components from the extrac-
tion procedure, the identification of the moiety to fully describe the protective 
immunity mechanism was difficult and other more defined antigens have been ex-
ploited. 
 
2.3.3 Cell wall component vaccines 
Fungal cell wall constituents are excellent candidates for vaccine development 
since the cell wall is a unique microbial feature with an important role in antigen 
presentation and immunomodulation [28]. Candida albicans cell wall is composed 
mainly of carbohydrates (80–90%), such as mannans, β-glucans and chitin, while 
proteins and lipids are a minority. β-glucans and chitin are located at the inner-
most layer of the cell wall, providing structural rigidity and strength, while man-
nans are abundant in the outer layer. Purified polysaccharide vaccines are poorly 
immunogenic and largely ineffective, due to the inability of the polysaccharide to 
induce T-cell responses. Thus, in glycan-based vaccines it is common to conjugate 
the polysaccharide to a carrier molecule such as the tetanus or diphtheria bacterial 
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toxoid [88], which are accepted for human use, or to peptides derived from the in-
fectious agent of interest [89]. Nevertheless, glycopeptides may still be poorly 
immunogenic and adjuvant has been also included, like the complete Freund’s ad-
juvant [89]. Previous studies have shown that the major cell wall components that 
elicit a host immune system response are proteins and mannoproteins, in which 
both the carbohydrate and protein moieties are important [89, 90]. Candida sur-
face mannans were used either alone, or encapsulated [91] or even conjugated 
with protein to induce protection against experimental disseminated candidiasis 
[92]. The formulations of mannans conjugated with BSA showed high levels of 
protection with 100% survival in a disseminated murine model. This study also 
suggested that di- and trisaccharides of mannans were more efficient than tetra-
penta- or hexasaccharides in inducing protective antibodies. In order to avoid the 
controversy of results that might be influenced by the distinct methods of mannans 
extraction the new approaches developed fully synthetic mannans conjugated vac-
cines. In this view a synthetic trisaccharide mannan-tetanus toxoid conjugated 
vaccine was used in experimental immunization protocol that was designed to 
simulate the clinical situation in which vaccination can be performed before a pa-
tient becomes immunocompromised by treatment with immunosuppressive drugs 
to induce leukopenia [93]. Although no survival rate was quantified in this study, 
this conjugate vaccine achieved a statistically significant reduction of fungal bur-
den in kidney and liver of immunized rabbits, when compared to controls and this 
was attributed to the high titer of specific IgG antibody capable of opsonizing the 
surface of C. albicans cells. This model indicated that even in leukocytopenic an-
imals a previous vaccination is able to induce resistance against disseminated can-
didiasis.  
Xin and collaborators [89] selected C. albicans cell surface proteins previously 
identified as inducers of antibodies during human candidiasis [62] to conjugate 
with β-mannan. The selected proteins were fructose-bisphosphate aldolase (Fba), 
methyltetrahydropteroyltriglutamate (Met6), hyphal wall protein-1 (Hwp1), 
glyceraldehyde-3-phosphate dehydrogenase (Gap1) and phosphoglycerate kinase 
(Pgk1). By using an antigen-pulsed DC-based vaccine strategy, immunization 
with β-(Man)3-Hwp1, β-(Man)3-Fba, or β-(Man)3-Met6 conjugates showed 80-
100% survival rate, while with β-(Man)3-Enol or β-(Man)3-Gap1 the survival rate 
was 40 or 80%, respectively. Curiously, in this study β-(Man)3-Pgk1 slightly en-
hanced disease. The β-(Man)3-Fba conjugate vaccine, that induced the highest 
protection, showed similar results against disseminated candidiasis in two differ-
ent mouse strains, BALB/c and C57BL/6 mice. However, the immunization pro-
tocol utilizing dendritic cells is cost prohibitive. Thus, β-(Man)3-Fba has been ex-
ploited in a subcutaneous immunization protocol using different adjuvants. After 
several approaches using of β-(Man)3-Fba with alum or MPL (Lipid A, mono-
phosphoryl) with no significant protection, the use of tetanus toxoid was able to 
restore protection previous observed and even protect 100% outbred mice [94]. 
The protective responses against Candida mannan components appeared to be 
mainly by induction of protective antibodies specific against the fungal peptide 
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epitopes and the conjugated polysaccharides, which enabled the production of an-
ti-polysaccharide IgG antibodies in vivo. The switch from IgM to IgG, the activa-
tion of the complement system and the rapid deposition of high amounts of factor 
C3b onto the yeast cell wall are mechanisms that contribute to inhibit Candida 
growth in vitro [89, 94, 95]. These results substantiate the role of antibody in pro-
tection against systemic candidiasis in the animal model, evidenced by high sur-
vival rates and reduced organ fungal burden. 
Although mannoproteins are the major components of the cell wall in eliciting 
immune responses, β-glucans were also exploited. However, due to their poor 
immunogenicity β-glucans must be also conjugated with other molecules. The 
brown alga Laminaria digitata β-1,3-glucans, the laminarin, has been exploited as 
immunizing antigen conjugated with the diphtheria toxoid and results showed it 
was protective against both mucosal and systemic candidiasis in mice, with a pro-
tective rate around 70% [88]. Remarkably, this laminarin vaccine strategy con-
ferred cross-protection to mice lethally challenged with the major fungal patho-
gens C. albicans, Aspergillus fumigatus and Cryptococcus neoformans [96]. The 
bacterial Calreticulin (Crt) protein is functionally similar to heat shock proteins 
and one of the main characteristics of this HSP family is that they possess a potent 
immunostimulatory activity. This characteristic was exploited as an effective car-
rier or adjuvant for β-glucans in assisting the production of glycotope-specific IgG 
antibodies in healthy as well as in immunocompromised mice. Laminarin conju-
gated with a peptide from Calreticulin (LAM-CRT) induced proliferation of B 
lymphocytes and production of specific laminarin and β-1,3-glucans IgG1 anti-
bodies, even in athymic (T-cell-deficient) nude mice [97]. Vaccination with LAM-
CRT protected mice against systemic C. albicans challenge with a survival rate 
around 60%. 
 
2.3.4 Vaccines for neutralizing virulence factors 
The previous approaches of vaccination were mainly based on the stimulation 
of the immune system with whole microbes or with constitutive microbial 
epitopes present at the surface of the infectious organism. However, the most ef-
fective human vaccines, which prevent tetanus and diphtheria, are directed against 
the bacterial toxins rather than against the structural epitopes. Thus, another ap-
proach in the development of immunoprotective therapies against fungal infec-
tions is the development of strategies that focuse on the neutralization of virulence 
factors, either present in the cell wall or secreted that should be produced by mi-
croorganisms in their pathogenic form [83]. Virulence factors include proteins in-
volved in the adhesion to and invasion of host tissues, secreted lytic enzymes, the 
morphogenetic yeast-to-hyphae switching, the maintenance of cellular integrity or 
the avoidance of the host immune response. 
In this view, vaccines based on the adhesins Als1p and Als3p were exploited. 
Als1p allows binding of C. albicans to human vascular endothelial cells and Als3p 
is a hypha-specific surface protein that also mediates attachment to epithelial and 
endothelial cells. In addition, Als3p is one of the adhesion molecules that is re-
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sponsible for the binding to host cell receptors, such as E-cadherin, and induce 
passive endocytose of C. albicans by host epithelial cells [38]. Intraperitoneal 
immunization of BALB/c mice with a recombinant N-terminal peptide of Als1p 
(rAls1p-N) induced modest protection against invasive candidiasis, protecting 
25% of the infected mice [98]. However, when a subcutaneous route of infection 
was tested, the protection rate was much higher, around 50 to 57% of immuno-
competent mice survive the lethal infection [99]. This vaccination regime was also 
applied to neutropenic mice that were challenged with a 10 time lower inoculum, 
with and overall survival of 88% versus 38% of the controls, as well as in a muco-
sal oropharyngeal candidiasis model, with results showing a clear reduction on in-
vasive tongue lesions. The recombinant N-terminal peptide of Als3p (rAls3p-N) 
was also exploited and compared with rAls1p-N [100]. Results indicated that 
rAls3p-N is as effective as rAls1p-N against disseminated candidiasis, with simi-
lar survival rates, around 40 to 50%, but was more effective than rAls1p-N against 
oropharyngeal or vaginal candidiasis. This high effectiveness in mucosal models 
may be due to the fact that Als3p mediated superior adhesion to epithelial cells 
than Als1p. 
These data showed promising results and rAls3p-N stand out as a candidate for 
further development of an anti-candidal vaccine. However, these vaccines used 
Freund’s adjuvant to enhance immunogenicity, which is not allowed for human 
use. In order to switch to an adjuvant approved for human use, these vaccines 
were tested with alum (Alhydrogel) but the efficacy was lower than with Freund’s 
adjuvant even using a higher dose of the recombinant proteins. The survival rate 
using Freund’s adjuvant ranged from 100% to 50% using 20 μg of rAls1p-N while 
with Alhydrogel diluted in phosphate-buffered saline (PBS) was of only 10% us-
ing 100 μg of rAls1p-N [101]. Regarding rAls3p-N, the protection of around 40 to 
50% with Freund’s adjuvant shifted to around 35% with 300 μg of antigen with 
Alhydrogel [102]. Interestingly, Als3p is structurally similar to the Staphylococcus 
aureus surface clumping factor (ClfA) that is also involved in adhesion, so these 
authors also tested for a cross-reactivity of rAls3p-N vaccine against S. aureus in-
fection in mice. Results showed that vaccination with rAls3p-N in Alhydrogel im-
proved the survival of mice subsequently infected with multiple clinical isolates of 
S. aureus (40% to 70% of survival rate) [103]. Although rAls1p-N and rAls3p-N 
vaccines induced broader antibody-based responses, antibody titers did not signif-
icantly correlate with survival in both recombinant peptides. Thus, the protective 
mechanism of these recombinant peptides was not correlated with protective anti-
bodies but was associated to enhancing cell-mediated immunity. In concordance 
with these observations B-cell-deficient mice showed the same pattern of re-
sistance while in T-cell-deficient (nude) the protection against systemic candidia-
sis previously observed was abolished. 
More recently, the efficacy of rAls3p-N vaccine with alum as adjuvant in pro-
tecting against vulvovaginal candidiasis was evaluated in a murine VVC model 
[56]. In this model, rAls3p-N induced a strong immune humoral response with 
high anti-rAls3p-N serum IgG and vaginal IgA titers. In addition, ex vivo killing 
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of opsonized C. albicans by neutrophils was correlated with significant decrease 
in vaginal fungal burden both in inbred and outbred mice infected with different 
clinical C. albicans isolates. As in previous studies, the role of B and T cells in 
vaccine-mediated protection was evaluated in B-cell-deficient and nude mice, re-
spectively, showing that contrary to the systemic model, rAls3p-N efficacy in the 
VVC model requires both B and T cells. 
Other virulence factors that were thought to be neutralized were the Secreted 
Aspartyl Proteinases (SAPs), an enzyme family with 10 members, from Sap1p to 
Sap10p. While Sap1p to Sap8p are secreted and released to the surrounding medi-
um, Sap9p and Sap10p remain bound to the cell-surface [2]. These ezymes are in-
volved in the degradation of mucous substrates and defensive factors, promoting 
Candida damage to epithelial and endothelial cells and helping the fungal cells to 
elude the host immune response. One of the early studies presented results of im-
munization against a secreted unidentified 43 000-MW protein, named p43, that 
resulted in the complete neutralization of its immunomodulatory effects, and was 
very efficient in protecting mice, i. e. no CFUs were observed in the kidney of 
vaccinated mice in comparison with the controls [104]. The mechanism of protec-
tion involved the production of protective specific antibodies against p43 evaluat-
ed by passive administration. In latter studies the same authors used C. albicans 
Sap2p, a 41 000-MW secreted protein that they believed to mediate some of the 
effects observed with p43. However, they concluded that although an immuno-
modulatory role for Sap2p on C. albicans was also observed, it appeared unlikely 
that p43 activities previously described were caused by Sap2p alone [105]. Never-
theless, this study assessed the potential of an intradermal (i.d.) vaccination with 
10μg Sap2p inoculum incorporated in alum adjuvant in preventing systemic can-
didiasis in BALB/c mice. After a lethal inoculum of C. albicans an effective pro-
tection was obtained in Sap2p immunized mice with a survival rate of around 
75%. The immune protection against systemic candidiasis in mice immunized 
with Sap2p is antibody-mediated as indicated by the correlation of survival with 
an increase in serum antibodies to Sap2p, and by the passive transfer of anti-Sap2 
IgG that significantly decreased yeast burden in kidneys of C. albicans-infected 
mice.  
Meanwhile, intravaginal (i.v.g) and intranasal (i.n.) immunizations with a Sap 
preparation, mainly consisting of Sap2p, showed that neutralization of these se-
creted proteins could also be effective in conferring protection against vaginal 
candidiasis in the rat model. An inoculum of 100μg of Sap with cholera toxin as 
adjuvant induced a high degree of protection against vaginal challenge with C. al-
bicans. This study showed that the i.n. route is as efficient as the i.v.g. in inducing 
protection against mucosal candidiasis and it is recognized that i.n. route is much 
more easy to subject compliance to self administration [106]. In order to specify 
the antigen to propose a candidate vaccine against mucosal candidiasis, a recom-
binant and truncated Sap2 protein (rSap2t) was produced and the immunization 
with this recombinant protein induced antibody-mediated protection against Can-
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dida infection in an experimental model of rat vaginitis, confirming the previous 
results [107].  
Hyr1p is an important virulence factor for C. albicans, a mannoprotein on the 
cell wall implicated in the resistance to phagocyte killing and another approach to 
induce protection used this protein [108]. Mice were immunized with a recombi-
nant fragment (rHyr1p-N) in complete Freund's adjuvant or in Alhydrogel and 
then infected with C. albicans. The results showed that vaccination with rHyr1p-N 
mixed with both adjuvants markedly improved survival in a range of 60% or 70%. 
The mechanism of resistance included the action of polyclonal antibodies specific 
to anti-rHyr1p that enhanced mouse neutrophil killing activity evidenced by the 
lower organ fungal burden [108]. In order to expand these findings to both immu-
nocompetent and neutropenic mice, and to evaluate if this vaccination strategy al-
so protects against non-albicans Candida spp, immunizations with rHyr1p-N in 
alum were tested. Results showed a dose dependent improved survival rates in 
immunocompetent mice compared to mice receiving adjuvant alone, with the best 
results observed with 33 µg of rHyr1p-N in alum (survival rate of around 40%). 
Vaccination with the highest dose also reduced the tissue fungal burden by ap-
proximately 16-fold when compared to control mice. This vaccine effectively pro-
tected neutropenic mice against candidiasis (survival rate of around 20%) and sig-
nificantly increased the mouse immune response as determined by detection of 
increased anti-rHyr1p-N antibody titers and reduced CFUs in kidneys. The 
rHyr1p-N vaccine also induced a significant reduction of tissue fungal burden of 
vaccinated mice and then infected with C. glabrata, C. parapsilosis and C. tropi-
calis. The mechanism of protection rendered by rHyr1p-N appears to be attribut-
ed, at least in part, to protective antibody response as evidenced by the results ob-
tained with passive immunization with purified rabbit anti-Hyr1p IgG prolonged 
survival of mice infected with C. albicans. 
Evidence has accumulated that antibodies specific for certain yeast cell surface 
epitopes may be protective and thus, screens for antibodies against those epitopes 
expressed during pathogenesis in human disseminated candidiasis have been per-
formed [59]. From these studies, some of the antigens responsible for the induc-
tion of antibodies identified during the convalescent-phase or that could be corre-
lated with higher probability of recovery were tested. Anti-wall enolase antibodies 
stand out as protective antibody and thus enolase was tested to evaluate if it would 
induce protection against a systemic infection in the mice model. 100μg of puri-
fied recombinant enolase (rEno1p) in complete Freund’s adjuvant were evaluated 
in an immunization protocol and results indicated to be effective in reducing the 
CFUs of organs of immunized mice [109]. The immune protection appeared to be 
mainly antibody-mediated as indicated by the increased titres of enolase-specific 
IgG1 and IgG2a in serum of immunized mice that enhanced opsonization mediat-
ed yeast killing by neutrophils. Passive transfer of anti-rEno1p also reduced fungal 
burden of non-immunized infected mice.  
Antibodies against heat-shock proteins, particularly anti-Hsp90p, have also 
been detected in sera from patients that recovered from invasive candidiasis in 
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contrast to those that did not survived and consequently Hsp90p, a cell wall pro-
tein, has been suggested as an important target for protective studies. In addition, 
Mycograb (Neu Tec Pharma) a monoclonal antibody binds to the immunodomi-
nant epitope of C. albicans Hsp90p has been applied in combined therapies with 
positive results [63]. Two strategies have been exploited, an Hsp90-expressing 
DNA vaccine and a recombinant Hsp90 protein vaccine [110, 111]. However, and 
although particularly the recombinant protein induced significant increases in both 
serum and vaginal hsp90-CA-specific IgG and IgA antibodies when compared to 
the control group these vaccination approaches did not elicit sufficient protection. 
 
In sum, the best protective effects observed to date have been stimulated by 
immunization with viable cells from virulent or avirulent C. albicans strains. 
Killed cells or subcellular components have been moderately successful and even 
less efficient in subunit vaccines. However, in the last years the focus on the de-
velopment of fungal vaccines has been placed on subunit vaccines that are easily 
controlled in terms of preparation and composition, enabling a more precise eval-
uation of their mechanism of action and good manufacturing practices. Although 
expectations for these vaccines are high, some authors think that for invasive can-
didiasis univalent vaccines are unlikely to be successful [64]. The reasons for the-
se disbelieve are mainly due to the fact that the most effective vaccines developed 
are against known virulence factors with inducing of protective antibodies. One of 
the main characteristic features of C. albicans is its extraordinary range of viru-
lence factors that are expressed by families of genes. Most of these gene families 
are composed of at least ten different members that in their action facilitate tissue 
invasion by enabling the fungus to escape from, modulate or even exacerbate host 
immunity, and in most situations play redundant roles. Thus, the univalent vac-
cines confer a considerable probability that the fungus can escape from immune 
responses induced by the vaccination strategy by compensatory expression of oth-
er virulence traits. Taking into account these observations, the use of at least two 
unrelated virulence associated fungal immunogens was recommended to be pre-
sent in the vaccine formulation, such as the Als3p and the Sap2p. 
Other approach to reduce the chances of immune evasion is to go back to the 
use of a more complex immunization antigen. A recent study used dithiothreitol 
(DTT) extracted C. albicans cell wall surface proteins (CWSP) as antigens incor-
porated into cationic liposomes as adjuvant/ delivery system. The cationic surfac-
tant dioctadecyldimethylammonium bromide (DODAB) and monoolein, 1-
monooleoyl-rac-glycerol (MO) were used to develop a DODAB:MO lipid based 
delivery system loaded with CWSP and determined its immunogenicity for the 
development of a vaccine against systemic Candida infection [112]. Results 
showed that immunized mice displayed strong humoral response, with high levels 
of IgGs against specific cell wall proteins, and re-stimulated splenocytes derived 
from mice immunized secreted high levels of IFN-γ and IL-17. This vaccine strat-
egy was able to protect around 70% of mice [113]. The main advantage of this 
system is that liposomes, as particulate carriers, entrap and protect the specific 
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protein(s) against degradation, enhancing APC uptake of the liposomes and acti-
vation.  
 
Many positive results have been achieved in the last years in the development 
of fungal vaccines. Technological developments have allowed for a rapid expan-
sion of the number of general strategies for making new vaccines and studies will 
continue, based on more comprehensive understanding of the immunobiology of 
pathogen, the type and specificity of immune response required for persistent pro-
tection against disease, the attainment of mucosal immunity and the optimal vac-
cination strategy to achieve protection. From all these studies, several candidate 
vaccines have been proposed and an important outcome is that the selection of an-
tigens and /or the complexation method of conjugation are critical since it may re-
sult in the development of potentially useful protective vaccine candidates or it 
may enhance disease susceptibility. Problems associated with conjugated vaccines 
such as, variation in antigen loading, immunogenic linkers, and antigenic carrier 
proteins must be considered. The important point, from the standpoint of anti-
body-mediated protection, is that the enormous antigenic complexity of the Can-
dida cell should not be expected to reliably induce production of protective anti-
bodies, as defined by specificity, titer, isotype and effector function. Candida 
albicans antigens that appeared to have potential immunoprotective responses 
seem to be proteins or glycoproteins components that play their structur-
al/physiological role outside the plasma membrane, belonging to the cell wall, or 
that are secreted to the exocellular environment.  
In recent years, advancement of vaccines has focused on improving immune-
adjuvant and the use of novel vaccine carriers. Some of these particulate carriers 
also show adjuvant properties. Herein, we will present the adjuvant carriers that 
are used in commercial vaccines, and the carriers that are being used in the devel-
opment of fungal vaccines. 
 
 
2.4 Licensed adjuvants carriers 
The main goal of vaccination is the induction of a protective immunity against 
a particular disease, and in some subunit vaccines this can only be achieved by 
addition of an adjuvant or adjuvant combinations. Sub-unit, highly purified anti-
gens may lack PAMPs needed to activate the innate immune system and down-
stream adaptive responses. It is thought that the use of adjuvants (Latin word ad-
juvare, meaning “to help or aid”) may help to overcome this first step on the 
innate immune response [114]. Thus, the choice of adjuvant/s is important since it 
can direct the type of adaptive immune response to the administered antigen, pref-
erentially activating specific T-cell responses. Adjuvants may also improve im-
mune responses in populations where responses to vaccines are typically reduced, 
such as infants, the elderly and the immunocompromised, which is the more vul-
nerable population for acquiring fungal infections. 
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Although adjuvants are important components of the vaccine strategy, their 
mechanisms of action only recently are being revealed [115]. Latest evidence sug-
gest that adjuvants may have one or more of the following mechanisms of action: 
(1) depot effect (sustained release of antigen at the site of injection), (2) cellular 
recruitment at the site of injection, (3) increase antigen uptake and presentation to 
APCs, (4) up-regulation of MHC II and co-stimulatory molecules and migration to 
the draining lymph nodes, (5) up-regulation of cytokines and chemokines, and (6) 
activation of inflammasomes [115]. The most widely recognized vaccine adju-
vants are aluminium based mineral salts, emulsions, virosomes, and liposomes, 
which are also considered delivery systems. 
 
The most well known adjuvants in vaccination strategies are aluminium based 
mineral salts, also known as alum. Aluminium salts consist of crystalline nanopar-
ticles that aggregate to form a heterogeneous dispersion of particles of several mi-
crons. They are highly charged and conducive, which allows the binding between 
the antigens or immunomodulatory molecules to alum due to strong electrostatic 
interactions [116, 117]. Regardless the progress in understanding aluminium salts 
its mode of action is still poorly understood. It is described that in the peritoneal 
cavity of mice alum induces recruitment of immune cells through induction of 
chemoattractants like CCL2 the neutrophil chemotaxin KC (CXCL1) and eosino-
phil chemotaxin eotaxin (CCL11) [118]. Eosinophils appear to have a crucial role 
in priming and differentiation of B cells, resulting in robust antibody production 
and Th2-type immune responses [119]. However, there is evidence suggesting that 
injection of alum leads to tissue damage and cell death with release of endogenous 
danger signals and inflamassome activation, which leads to the release of IL-1β, 
IL-18, in a caspase-1 dependent manner [120]. There are some conflicting results 
with regard to the role of inflammasomes in adjuvant activity of alum but the most 
recent idea is that inflammasomes activation by alum might play an important role 
in activating innate immunity, but the contribution of inflammasomes in activation 
of adaptive immunity remains unclear [119]. Aluminum adjuvants act primarily to 
increase antibody production and are therefore suitable for vaccines targeting 
pathogens in which the antibodies mediated killing is important, therefore may not 
be suitable for vaccine strategies where a strong cellular immunity is essential.  
 
An emulsion is a mixture of two non-miscible liquids and an emulsifier that is 
required to stabilize the emulsion by increasing its kinetic stability. Depending on 
the water-to-oil ratio, the type of emulsifier, and the mixing procedure, a water-in-
oil (W/O) or an oil-in-water (O/W) emulsion may be produced [121]. The MF59 
was the first oil-in-water adjuvant to be developed and approved for use in human 
vaccines and it is the second most frequently used in licensed vaccines after alum. 
It is composed by squalene, polysorbate 80 and sorbitan trioleate. Similar to alum, 
MF59 also induces the release of the chemokines such as CCL2, CCL3, CCL4 and 
CXCL8, which are involved in cell recruitment from blood into peripheral tissue. 
MF59 also accelerates and enhances monocyte differentiation into DCs, augments 
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Ag uptake, and facilitates migration of DCs into tissue-draining lymph nodes to 
prime adaptive immune responses [122]. MF59 does not seem to be correlated 
with enhanced antibodies titers and it is seems to induce balanced Th1/Th2 re-
sponses [115]. 
Freund’s adjuvants were the earlier used emulsion adjuvants. Freund’s com-
plete adjuvant (FCA) is a mixture of 85%mineral oil (Marco 52) and 15% emulsi-
fier (Arlacel A, mannide monooleate) prepared with 500 μg/ml of heat-killed and 
dried Mycobacterium tuberculosis. Incomplete Freund’s adjuvant (IFA) lacks the 
mycobacterial component, making it safer but less potent. However, Freund’s ad-
juvants were considered too reactogenic for continued use in humans [123]. 
More recently two new emulsions, Adjuvants Systems 03 (AS03) and 04 
(AS04), were developed. AS03 is composed of squalene, α-tocopherol and poly-
sorbate 80, while adjuvant AS04 is composed of monophosphoryl lipid A prepara-
tion (MPL) and aluminum salt. AS04 was shown to induce optimal immune re-
sponses only when co-localized with antigen, providing a depot effect [124]. The 
depot effect at the injection site is the most widely recognized mechanism of ac-
tion of adjuvants. This slow release of antigens ensures constant stimulation of the 
immune system and has been correlated with production of high antibody titers. 
Recent evidence indicates that this is not the main mechanism of action of alum or 
MF59. AS04 was also found to induce maturation of DCs (via TLR4), which then 
trafficks to the draining lymph nodes to activate antigen-specific T cells [124]. 
AS03 was found to up-regulate cytokines, such as colony-stimulating factor 3 
(CSF3) and IL-6 and chemokines as CCL2, CCL3, and CCL5, which then leads to 
cellular recruitment at the injection. The mononuclear cells after taking up antigen 
traffick to draining lymph nodes [125]. These data suggest that the direct effects of 
AS04 and AS03 adjuvants are on innate immune cells and effectors, activating of 
APCs and trafficking to draining lymph node, and also inducing secretion of cyto-
kines and chemokines. It is described that these effects will enhance antibody re-
sponses and Th1 responses [115, 124, 125]. 
 
Virosomes are spherical unilamellar vesicles of phospholipid carrying envelope 
virus proteins on their surface or encapsulated within the lumen [126]. Influenza 
virosomes have been used in the first vaccine to use an adjuvant other than alumi-
num, a vaccine against hepatitis A licensed in 1994 [126]. Influenza virosomes en-
sures robust and long-lasting immune responses against subunit antigens with an 
excellent safety profile. The adjuvant effect of virosomes is once more related to 
their ability to enhance antigen processing and presentation by APCs. Through fu-
sion of the virosome membrane with the membrane of endosomes or phagosomes 
the encapsulated protein antigens gain direct access to the MHC class I presenta-
tion pathway [127]. In addition, virossomes can also deliver their contents to DCs, 
MHC class I and class II molecules and induce maturation of DCs, being able to 
activate T helper cells [128]. This phenomenon of presentation of antigen located 
in the MHC-class II pathway to MHC-class I pathway is called “cross presenta-
tion” and helps the development of both T helper and T cytotoxic responses, 
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against the antigen [129]. This cross-presentation has been considered a major fo-
cus to the success of producing an effective immune response to a vaccine, partic-
ularly against intracellular parasites. The cytokine profile induced by virosomes, 
including TNF-α, GM-CSF, IFN-γ and IL-2, is consistent with a Th1 response. 
 
Liposomes are double or multilayered, biodegradable carrier vesicles made up 
of phospholipids and/or synthetic lipids that consist of a lipid bilayer shell with an 
aqueous core. Liposomal formulations can be tailored in terms of the lipid compo-
sition, the liposomal charge, the size/lamellarity and/or the membrane fluidity in 
order to obtain optimal retention of different types of antigens, including adju-
vants, and enhancement of the desired vaccine-specific immune responses [130]. 
The conjugation of hydrophilic molecules in the surface of liposomes is also pos-
sible and further facilitates the uptake by phagocytes [131]. In addition, liposomes 
are highly acceptable by the human body and present low toxicity. From these 
characteristics liposomes are, without any doubt, the most studied carrier system 
and the interest for liposome-based vaccines has markedly increased over the last 
decades. 
The lipids selected for liposomal system will ultimately determine their proper-
ties and ability of inducing maturation of DCs, which is important to achieve an 
optimized vaccine carrier. The particle size governs cellular trafficking to second-
ary lymph nodes, antigen uptake, and cellular responses and it has been described 
that small particles (20–200 nm) drain freely towards lymph nodes, while large 
particles (500, 1000 nm) are dependent on DCs for transport to the lymph nodes 
[132]. The selection of the type of lipids also determines liposomal membrane flu-
idity, which is linked to cellular trafficking and antigen presentation to APCs. It 
has been determined that rigid, saturated dimethyl dioctadecyl ammonium (DDA) 
lipid greatly enhances priming ability of Th1-directed immune response, com-
pared with a fluid unsaturated lipid [133]. The surface charge of the liposome, the 
zeta potential value, is also determined by their lipid composition and dictates the 
colloidal stability of the formulation. The surface charge of liposomes has a major 
importance in the immune response, with cationic liposomes having an advantage 
over their neutral and anionic counterparts [131]. Indeed, the high surface density 
of positive charges offers an important platform for antigen adsorption due to elec-
trostatic interactions. Moreover, the interaction between the positively charged 
liposomes and the negatively charged membranes of APCs facilitates liposome 
uptake, increasing the vaccine potency without the need to increase the concentra-
tion of antigen [134]. In addition, the depot effect at the site of injection has also 
been described for the cationic adjuvant formulation (CAF) 01, a combination of 
DDA / TDB (trehalose-6,6-dibehenate) which is currently in phase I clinical trial 
[115, 135]. 
 
In sum, an essential point in the investigation of modern adjuvants is not only 
the initiation of a potent adequate immune response but mainly targeting APCs re-
ceptors to achieve such response avoiding as much as possible the toxicity associ-
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ated. Moreover, the ideal adjuvant should be able to promote an antigen-specific 
immune response, and should be nontoxic, biocompatible, readily biodegraded 
and eliminated, inexpensive to produce, stable before administration, and physico-
chemically well defined to facilitate quality control important to ensure reproduci-
ble manufacturing and activity. 
 
 
2.5 Vaccine strategies against Candida infections that advanced to clinical 
trails 
 Many positive results have been achieved in the development of fungal vac-
cines in the last years. However, few vaccine formulations directed against C. al-
bicans have successfully completed Phase I clinical trials, and although the major-
ity of the studies are concerned with the development of vaccines against systemic 
candidiasis the only approaches that enter clinical trails were against recurrent 
vulvovaginal candidiasis (VVC). The first study described in the literature is the 
Phase II study of D.651, an oral vaccine designed to prevent VVC prepared with 
C. albicans ribosomes and membrane proteoglycan from a nonencapsulated 
Klebsiella pneumoniae as adjuvant [136]. Latter, the PEV-7 from Pevion Biotech 
(Ittigen, Switzerland) composed of an antigen fragment of Sap2p embedded in a 
virosomal formulation with intrinsic adjuvanticity was proposed against VVC in-
fection. Finally, the NDV-3 from NovaDigm Therapeutics (USA) based on a re-
combinant protein fragment from Als3 with alum as the adjuvant is also in Phase 
1b/2a clinical trial to evaluate NDV-3 again in patients diagnosed with VVC.   
The preliminary phase II study of D.651 vaccine was conducted in 22 women 
with a history of frequent recurrences of vulvovaginal candidiasis. Vaccine was 
taken orally and administered intermittently over six months in capsules. The vac-
cine was well tolerated and reduced an average of 3.59 attacks of VVC per 6 
months to and average of 0.55 attacks per 6 months. However, this trial was con-
ducted without placebo and no further studies on this vaccine have been docu-
mented. 
The PEV7 vaccine is based on a truncated and enzymatically inactive recombi-
nant aspartyl proteinase-2 (rSap2) of C. albicans presented on the surface of influ-
enza virosomes [106, 107, 137]. PEV7 was considered to be safe in a repeated-
dose toxicological study in rats and generated a robust serum IgG and IgA anti-
Sap2 antibody response in mouse and rat models after intramuscular and intravag-
inal immunizations. Phase I clinical trial used lyophilized virosome formulations 
for intramuscular and intravaginal application with the intention to assess the safe-
ty and immunogenicity of PEV7 via a systemic prime/mucosal boost regime in 48 
healthy volunteers. Half of the women received intramuscular injections, while the 
other half received intravaginal capsules. This capsular formulation for intravagi-
nal application represents an innovation with the advantage of an easier admin-
istration, favoring patient compliance. Results showed that 100% of the vaccinated 
women developed specific and functional B cell memory. Both routes of vaccina-
tion induced a rapid and specific production of antibodies either in serum and/or 
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cervicovaginal secretion, which was very encouraging with regards to the thera-
peutic potential of the vaccine [138]. A summary of the study can be found at clin-
icaltrials.gov website, identifier number NCT01067131. 
The NDV-3 trial is a multi-center, double-blind, randomized, placebo-
controlled study to evaluate the safety, tolerability, immunogenicity and efficacy 
of this vaccine. Due to previous results, this vaccine was developed to treat and 
prevent infections caused by Candida but also to Staphylococcus aureus, being the 
first vaccine to demonstrate preclinical cross-kingdom potential [103]. This Phase 
1b/2a trial involved 188 patients from multiple centers in the United States with 
the aim to study and estimate the effect of a single, intramuscularly-administered 
dose of NDV-3, as compared to placebo, by evaluating safety and tolerability, as 
well as humoral and cellular immune responses. The study will also summarize 
recurrence of VVC over six- and 12-month period, time-to-onset of first VVC epi-
sode and severity of subsequent VVC episodes. A summary of the study can be 
found at clinicaltrials.gov website, identifier number NCT01926028. 
 
 
2.6 Concerns to overcome to further advance in fungal vaccines 
The development of innovative vaccines to protect patients from fungal and 
bacterial infections that can be recurrent, drug-resistant, and in some cases life-
threatening are still necessary. Other vaccines are ready to enter clinical trials if 
industrial interest and sufficient monetary support can be raised. Nevertheless, 
there are still some crucial points to solve such as: (1) the majority of the studies 
were performed in animal models that have limitations, (2) further understanding 
of the mechanisms of the C. albicans-host interaction in mucosal and systemic in-
fections, (3) the development of autoimmunity.  
The majority of the studies have been developed in animal models, that alt-
hough very useful do not fully recapitulate infection by the opportunistic com-
mensal C. albicans. Mice and humans are undoubtedly substantially different re-
garding their innate immune response to Candida. One of the main limitations is 
that, unlike humans, mice do not have a C. albicans GI flora and they lack Can-
dida serum antibodies. Several attempts to develop a more real model have been 
made, and there has been indications that Candida-colonized mice were able to 
developed fungal-specific antibodies in the serum due to the colonization and that, 
these animals if immunized with a specific protein, were able to develop specific 
antibodies to that immunogen [139]. However, the information that can be gained 
from using such mice is still limited. The consequences may be that vaccines that 
are very efficient in the animal model could be less effective in human, and the 
protection of the vaccine is not persistent or high-grade or cause unacceptable tox-
icity. Thus, in preclinical trials the effectiveness of vaccines should be tested in 
different species of animals, including mice, rabbits and monkeys. The infection 
models could include immune-normal animals, immune-deficient animals, and 
could involve variations in the symbiotic bacteria. 
To design any vaccine the mechanisms that confer protective immunity in the 
host against fungi must be fully understood. This knowledge is important in the 
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selection for constituents from the fungus that elicit the particular type of immune 
response. In addition, there is little control of the C. albicans strain used in the 
studies, the dose of the inocula to produce the intended outcome of death or tissue 
infection, the dosage and delivery time of the vaccines to produce the greatest pro-
tection effect, information regarding the different outcomes form various routes of 
Candida infection, or the multiple parameters tested, such as tissue CFU and sur-
vival rates. This is further complicated in the development of a multivalent vac-
cine. Although substantial advances have been made in the understanding of host-
Candida interactions, the current paradigm of C. albicans-specific immunity sug-
gests that pathogenic growth of the fungus is prevented by a combination of innate 
and adaptive Th1/Th17 responses, which activates phagocytes as the major candi-
dacidal effectors [33, 58]. However, despite the idea that Th17 cells are protective 
against fungal infections, recent studies suggest that inflammatory Th17 and Treg 
responses are protective at mucosal surfaces but in systemic candidiasis a time de-
pendent and coordinated Th17/Treg response is fundamental for a positive out-
come [63]. The balance between protective versus pathogenic immunity is crucial 
in determining the disease outcome. This is one of the reasons that justify why 
vaccines against mucosal candidiasis have advanced to clinical trails. Another 
concern in the development of subunit vaccines is the adjuvant used. Adjuvants 
have been used for long time but their mechanisms of action are not fully under-
stood. They may act by a combination of various mechanisms to create a local 
immuno-competent environment at the injection site. Many of the preclinical stud-
ies were conducted using adjuvants that are not recommended for human use such 
as the Freund’s adjuvant, and when switched to an adjuvant recommended the re-
sults were not the same, and in many cases were lower than expected. In addition, 
and probably due to the lack of knowledge about their mechanism of action, adju-
vants are selected just taking into consideration what is in use. Adjuvants should 
be selected depending on the type of innate responses that are needed to be acti-
vated, because they may alter the quality and quantity of adaptive immune re-
sponses. That is why just changing the adjuvant without considering its mecha-
nism of action may not produce the expected results. Thus, more studies should be 
developed in order to better understand the mechanisms of action of adjuvants, 
providing critical information that will help in a rational design of vaccines and in-
form on adjuvant safety. These informations will lead to the recommendation of 
new adjuvants for human use. 
 
The development of autoimunity was always an important concern, particularly 
in the case of commensal species as C. albicans. Keeping the balance of the im-
mune system in eliminating invading pathogens, while still maintaining self-
tolerance to avoid autoimmunity, is critical for the body’s health. In this balance, 
the mucosa microbiota provides benefits to the host by actively participating in the 
regulation of immune homeostasis. These evidences are confirmed by the conse-
quences of altering the gut microbial communities, termed dysbiosis, such as the 
autoimmune disorders. The mucosa microbiota has a profound effect on both the 
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innate and adaptive immune system so it is not surprising that some members of 
the microbiota have been linked to autoimmune diseases. It has been determined 
that the microflora of mice with colitis fails to metabolize tryptophan into metabo-
lites that act as aryl hydrocarbon receptor (AHR) ligands, modulating production 
of IL-22, an important cytokine for intestinal homeostasis [140]. Intestinal in-
flammation is attenuated after inoculation of mice with three Lactobacillus strains 
capable of metabolizing tryptophan or by treatment with an AHR agonist. Despite 
difficulties in fungal DNA extraction methods and fungal identification methods, 
the gut, oral, lung and skin niches presented four genera in common: Aspergillus, 
Candida, Cryptococcus, and Penicillium [141]. Fungi have long been suspected to 
be involved in inflammatory bowel disease (IBD) pathogenesis since many genes 
involved in the immune response against fungi have associated single nucleotide 
polymorphisms (SNPs) in IBD patients, such as in DECTIN-1, CARD9 or 
NFkBp105 genes in the signaling pathways of antigen-presenting cells, and 
IL12p40, IL23R or IL-6ST, cytokines and cytokine receptors involved in Th17 
and Th1 polarization, among others [142]. These findings suggest a role of fungi 
in inflammatory pathogenesis. Thus, it is not surprising to find that fungi, and par-
ticularly C. albicans, is more abundant in the gut microbiota of these patients. But 
this enhancement in the fungal population is particularly related to a genetic defect 
in microbial sensing in the susceptible human population. Using animal models, 
gut inflammation induced by dextran sodium sulfate (DSS) promoted C. albicans 
growth and this growth enhances inflammation. Thus, it seems that there is a vi-
cious circle in which intestinal inflammation induces C. albicans proliferation, 
which itself enhances the inflammatory process. That is why it is described that C. 
albicans has a negative impact on inflammation. Thus, any factor that significant-
ly alters the local microbiota such as prolonged use of broad-spectrum antibiotics, 
enhances the fungal population in the microbiota and augments intestinal inflam-
mation, contributing to the initiation of the vicious circle and enhancing the 
changes of fungi translocation and systemic infection. But this predisposition to 
increased inflammation may not be a direct action of Candida in inducing the au-
toimmune dysfunction, unless patients present genetic defect in fungi sensing. In-
deed, host genes affect the composition and function of the gut microbiota. 
In order to induce an autoimmune dysfunction, vaccination against C. albicans 
either enhances chronic inflammation, particularly at the mucosa, or develops an 
adaptive response against an epitope similar to a human molecule. Antibodies 
against Saccharomyces cerevisiae mannan as well as against other fungal cell wall 
components, such as anti-laminarin that identifies β-1,3-glucans and against β-
1,4-N-acetylglucosamine, present in the chitin layers, have been shown to be asso-
ciated with Crohn's disease [141, 143]. But once more, the existence of these anti-
bodies may be due to the fact that in susceptible individuals intestinal inflamma-
tion induces C. albicans proliferation, enhancing the changes of fungi 
translocation and being seen by the immune system. There is no evidence that in 
normal individuals the presence of these antibodies enhance the probability of 
mucosa inflammation. On the contrary, from the vaccination studies against Can-
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dida vaginal infections, a reduction in the inflammation sign as well as a local re-
duced fungal burden is documented [144]. However, regarding vaccine develop-
ment studies against systemic candidiasis mucosal inflammation is not a parameter 
that is frequently included in these studies. Thus, the study of the induction of in-
flammatory at the mucosa should also be included in the studies addressing sys-
temic candidiasis.  
In terms of cross-reactions responses against molecules/epitopes with homolo-
gy to human molecules, epitope mapping analysis has showed that some heat 
shock proteins epitopes from C. albicans may have as much as 100% direct ho-
mology with human heat shock proteins [76]. Thus, antibodies developed against 
the heat shock proteins, particularly Hsp90p raise the concern of development of 
autoimmune reactions. In children idiopathic short stature with C. albicans and/or 
H. pylori gut colonization it was reported that the incidence of autoantibodies 
against selected neuropeptides is high due to molecular mimicry between antigens 
of these microbiota and the selected neuropeptides [145]. However, further studies 
are necessary to elucidate this issue. To avoid induction of these autoantibodies by 
vaccination the selection of target molecules is essential, molecules that are unique 
to the fungi should be addressed and an epitope mapping analysis should always 
be performed. 
 
In summary, despite the advances in our knowledge and understanding in patho-
genesis and immune responses, invasive fungal infections continue to result in 
significant morbidity and mortality in critically ill patients. The traditional anti-
fungal chemotherapy has met some limitations, such as the toxicity and emergence 
of resistance, limiting their effectiveness. Therefore, there is an urgent need to im-
prove treatment options for these patients and vaccines can represent novel ap-
proaches against fungal infections. Although the currently available vaccines have 
demonstrated good protection, there still a long way to go to before a vaccine to be 
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